International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (9) ; 10.12208/j.ijcr.20250458 .
总浏览量: 104
1 延边大学附属医院血液科 吉林延吉
2 延边大学 吉林延吉
*通讯作者： 刘萌萌,单位： 延边大学附属医院血液科 吉林延吉；
多发性骨髓瘤（MM）是一种复杂的骨髓浆细胞恶性增殖性疾病，其临床表现多样且预后不佳。近年来，microRNA（miRNAs）作为重要的非编码调控分子，在MM的发病机制、疾病进展、药物耐药及预后评估中显示出关键作用。本文综述了近十年来MM相关miRNAs的研究进展，重点分析了miRNAs在MM病理机制中的作用，并探讨了其在疾病的诊断、预后评估及靶向治疗中的应用潜力以期为MM的早期诊断和个体化治疗提供新的思路和策略。
Multiple myeloma (MM) is a complex malignant proliferative disease of bone marrow plasma cells, characterized by diverse clinical manifestations and poor prognosis. In recent years, microRNAs (miRNAs), as important non-coding regulatory molecules, have been shown to play a crucial role in the pathogenesis, disease progression, drug resistance, and prognostic evaluation of MM. This article reviews the research progress of MM-related miRNAs over the past decade, focuses on analyzing the role of miRNAs in the pathological mechanism of MM, and explores their application potential in disease diagnosis, prognostic evaluation, and targeted therapy, aiming to provide new ideas and strategies for the early diagnosis and individualized treatment of MM.
[1] 阿纳尔, 贾国荣. 多发性骨髓瘤中表观遗传学修饰的研究进展[J]. 现代肿瘤医学, 2022,30(21):4000-4004.
[2] 袁杰, 申娴娟, 景蓉蓉, 等. 多发性骨髓瘤相关信号通路与miRNA相互调控的研究进展[J]. 临床检验杂志, 2015, 33(09):698-702.
[3] Zhang J, Luo C, Long H, et al. Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma[J]. Int J Biol Markers, 2024,39(4):301-309.
[4] Roseth Aass K, Nedal T M V, Anshushaug Bouma S, et al. Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival[J]. Br J Cancer, 2023,128(4):656-664.
[5] Liu X, Qin L, Li W, et al. MicroRNA-1179 targets Epiregulin (EREG) regulates the proliferation and metastasis of human multiple myeloma cells[J]. Acta Biochim Pol, 2023,70(2):389-393.
[6] Liu Z, Han M, Meng N, et al. lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma[J]. Oxid Med Cell Longev, 2021,2021:9969449.
[7] Zhang H, Du Z, Tu C, et al. Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma[J]. Cancer Res, 2024,84(1):39-55.
[8] Liu W, Wang X, Zhang X, et al. Shear stress-mediated downregulation of miR-423-5p in M2 macrophage exosomes promotes osteogenic differentiation of bone marrow mesenchymal stem cells[J]. Int Immunopharmacol, 2025,164:115298.
[9] Bamfield-Cummings S, Silva J, Karim Z A. A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma[J]. SAGE Open Med, 2025,13: 352787994.
[10] Zhang Z, Li Y, Geng C, et al. Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma[J]. Biomed Res Int, 2019,2019:1575468.
[11] Moura S R, Abreu H, Cunha C, et al. Circulating microRNAs Correlate with Multiple Myeloma and Skeletal Osteolytic Lesions[J]. Cancers (Basel), 2021,13(21).
[12] Chen H, Cao W, Chen J, et al. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28[J]. J Cell Biochem, 2021,122(3-4):305-314.
[13] Pula A, Robak P, Robak T. MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance[J]. Curr Med Chem, 2021,28(33):6753-6772.
[14] Xu L, Xie Z, Jiang H, et al. Identification and evaluation of a six-lncRNA prognostic signature for multiple myeloma[J]. Discov Oncol, 2024,15(1):204.
[15] Papanota A, Karousi P, Kontos C K, et al. Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background[J]. Int J Mol Sci, 2021,22(5).
[16] Wu Z, Zhang Y, Yang Z, et al. Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion[J]. Cancer Cell Int, 2021,21(1):187.
[17] Soliman A M, Lin T S, Mahakkanukrauh P, et al. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma[J]. Int J Mol Sci, 2020,21(20).
[18] Raimondo S, Urzi O, Conigliaro A, et al. Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma[J]. Cancers (Basel), 2020,12(2).
[19] Soliman A M, Das S, Teoh S L. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis[J]. Int J Mol Sci, 2021,22(14).